Inhaled EXO-CD24 kept 85% of patients with ARDS free of respiratory failure at day 7 vs 33.3% with placebo in a 90-patient phase 2b trial.
|Articles|November 15, 2014
- BioPharm International-11-15-2014
- Volume 2104 eBook
- Issue 4
Optimizing Resin Performance with Disposable Chromatography Solutions
Author(s)Randi Hernandez
An increased need for higher-capacity resins and the demand for smaller batches has made disposable chromatography a more viable option.
Advertisement
Although the initial uptake of single-use chromatography solutions has been relatively slow, an increased need for higher-capacity resins and the demand for smaller batches has made disposable chromatography a more viable option.
from BioPharm International’s 2014 Secure Single-Use Systems eBook.
Articles in this issue
almost 12 years ago
Innovations in Single-Use Bioprocessing Componentsalmost 12 years ago
Budgets Increase to Support Single-Use Bioprocessingalmost 12 years ago
Security of the Single-Use Supply Chain: Is Dual Sourcing the Answer?almost 12 years ago
Trends in Single-Use BioreactorsAdvertisement
Related to this article
Nuravax will test AV-1959R in a 160-adult phase 2 trial to see whether the amyloid vaccine can prevent Alzheimer disease before symptoms begin.
In the phase 3 SHINE-2 trial, half of pediatric patients who responded to mirikizumab induction were in clinical remission at week 52. Lilly plans to file for a pediatric UC label expansion.
Guselkumab (Tremfya) sustained perianal fistula healing through 1 year in Crohn disease, with remission climbing to 35% in one FUZION dosing arm.
Interim phase 1/2 data presented at Retina in Rio 2026 showed sustained visual improvements with Opus Genetics’ AAV8 gene therapy OPGx-LCA5 and improved retinal sensitivity with OPGx-BEST1 in inherited retinal diseases.
Nathan Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about rare disease treatment development and navigating the FDA’s Rare Pediatric Disease Priority Review Voucher Program.
Mirikizumab (Omvoh) achieved comprehensive disease control in 27.7% of UC patients and deep remission in 20.4% with Crohn disease at 1 year.
As ArsenalBio, TScan, Bristol Myers Squibb, and others abandon ex vivo programs for in vivo engineering, early clinical data and platform differences point to both the promise and the unresolved safety, manufacturing, and regulatory questions of generating CAR-T cells inside the body.
Advertisement
Advertisement
Trending on BioPharm International
1
Regeneron's Libtayo Earns CHMP Nod for Expanded EU Dosing
2
Roche, Hansoh Sign Second ADC Pact Covering Preclinical and Roche-Selected Targets
3
Biomarker Testing Gaps Can Stall Targeted Oncology Therapy, BMS’s Dr Pennell Says
4
Nuravax Alzheimer Vaccine AV-1959R Earns FDA Fast Track Designation
5